In the prospective COG trial in children with high-risk neuroblastoma, patients randomised to dinutuximab (ch14.18 produced in SP2/0 cells [7]) in combination with i.v. IL-2 and GM-CSF, CNS toxicity was reported in 6 of 137 patients (4.4%) and manifested as encephalopathy, confusion, psychosis and seizure [3]. The gene discussed is CSF2; the disease is Encephalopathy.